Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Diseases of failed inflammation resolution are common and largely incurable. Therapeutic induction of inflammation resolution is an attractive strategy to bring about healing without increasing susceptibility to infection. However, therapeutic targeting of inflammation resolution has been hampered by a lack of understanding of the underlying molecular controls. To address this drug development challenge, we developed an in vivo screen for proresolution therapeutics in a transgenic zebrafish model. Inflammation induced by sterile tissue injury was assessed for accelerated resolution in the presence of a library of known compounds. Of the molecules with proresolution activity, tanshinone IIA, derived from a Chinese medicinal herb, potently induced inflammation resolution in vivo both by induction of neutrophil apoptosis and by promoting reverse migration of neutrophils. Tanshinone IIA blocked proinflammatory signals in vivo, and its effects are conserved in human neutrophils, supporting a potential role in treating human inflammation and providing compelling evidence of the translational potential of this screening strategy.

Original publication

DOI

10.1126/scitranslmed.3007672

Type

Journal article

Journal

Sci Transl Med

Publication Date

26/02/2014

Volume

6

Keywords

Animals, Animals, Genetically Modified, Anti-Inflammatory Agents, Apoptosis, Cell Movement, Cells, Cultured, Disease Models, Animal, Diterpenes, Abietane, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Green Fluorescent Proteins, High-Throughput Screening Assays, Humans, Inflammation, Larva, Neutrophil Infiltration, Neutrophils, Signal Transduction, Time Factors, Translational Medical Research, Zebrafish